Hofseth BioCare ASA (OSL:HBC)
Norway
· Delayed Price · Currency is NOK 2.100
+0.010 (0.48%)
Mar 13, 2025, 1:17 PM CET
Hofseth BioCare ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 256.83 | 190.82 | 119.13 | 76.88 | 52.51 | Upgrade
|
| Other Revenue | 8.71 | 27.7 | 1.32 | 10.74 | 16.74 | Upgrade
|
| Revenue | 265.54 | 218.51 | 120.45 | 87.62 | 69.25 | Upgrade
|
| Revenue Growth (YoY) | 21.52% | 81.42% | 37.47% | 26.52% | 2.17% | Upgrade
|
| Cost of Revenue | 169.55 | 165 | 102.49 | 77.05 | 39.53 | Upgrade
|
| Gross Profit | 95.99 | 53.51 | 17.96 | 10.57 | 29.72 | Upgrade
|
| Selling, General & Admin | 70.67 | 76.25 | 76.03 | 60.35 | 42.64 | Upgrade
|
| Other Operating Expenses | 90.62 | 43.38 | 40.13 | 39.43 | 52.33 | Upgrade
|
| Operating Expenses | 201.07 | 156.04 | 146.39 | 129.13 | 121.74 | Upgrade
|
| Operating Income | -105.08 | -102.53 | -128.43 | -118.56 | -92.02 | Upgrade
|
| Interest Expense | -15.69 | -7.54 | -9.95 | -9.39 | -9.22 | Upgrade
|
| Interest & Investment Income | 0.79 | 0.55 | 0.65 | 0.61 | 0.55 | Upgrade
|
| Earnings From Equity Investments | -5.59 | 2.54 | -0.2 | 0.03 | -0.78 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.16 | 0.3 | 0.74 | 0.91 | -0.54 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -0 | - | -0.06 | -0.09 | Upgrade
|
| EBT Excluding Unusual Items | -123.41 | -106.68 | -137.2 | -126.46 | -102.09 | Upgrade
|
| Asset Writedown | - | - | -0.19 | - | - | Upgrade
|
| Pretax Income | -123.41 | -106.68 | -137.39 | -126.46 | -102.09 | Upgrade
|
| Earnings From Continuing Operations | -123.41 | -106.68 | -137.39 | -126.46 | -102.09 | Upgrade
|
| Minority Interest in Earnings | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Net Income | -123.41 | -106.68 | -137.39 | -126.46 | -102.09 | Upgrade
|
| Net Income to Common | -123.41 | -106.68 | -137.39 | -126.46 | -102.09 | Upgrade
|
| Shares Outstanding (Basic) | 411 | 395 | 375 | 358 | 334 | Upgrade
|
| Shares Outstanding (Diluted) | 412 | 395 | 375 | 358 | 334 | Upgrade
|
| Shares Change (YoY) | 4.26% | 5.43% | 4.72% | 7.25% | 8.95% | Upgrade
|
| EPS (Basic) | -0.30 | -0.27 | -0.37 | -0.35 | -0.31 | Upgrade
|
| EPS (Diluted) | -0.30 | -0.27 | -0.37 | -0.35 | -0.31 | Upgrade
|
| Free Cash Flow | -12.26 | -5.43 | -49.19 | -84.7 | -94.21 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.01 | -0.13 | -0.24 | -0.28 | Upgrade
|
| Gross Margin | 36.15% | 24.49% | 14.91% | 12.06% | 42.92% | Upgrade
|
| Operating Margin | -39.57% | -46.92% | -106.63% | -135.32% | -132.88% | Upgrade
|
| Profit Margin | -46.47% | -48.82% | -114.06% | -144.34% | -147.42% | Upgrade
|
| Free Cash Flow Margin | -4.62% | -2.49% | -40.84% | -96.68% | -136.04% | Upgrade
|
| EBITDA | -65.3 | -89.83 | -118.46 | -104.57 | -79 | Upgrade
|
| EBITDA Margin | -24.59% | -41.11% | -98.35% | -119.35% | -114.08% | Upgrade
|
| D&A For EBITDA | 39.78 | 12.7 | 9.97 | 14 | 13.02 | Upgrade
|
| EBIT | -105.08 | -102.53 | -128.43 | -118.56 | -92.02 | Upgrade
|
| EBIT Margin | -39.57% | -46.92% | -106.63% | -135.32% | -132.88% | Upgrade
|
| Revenue as Reported | 265.54 | 218.51 | 120.45 | 87.62 | 69.25 | Upgrade
|
| Advertising Expenses | - | 13.49 | 15.04 | 13.03 | 7.86 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.